Antihypertensive ‘Edarbi’ acquires approval from MFDS
Takeda Pharmaceuticals Korea(CEO Mahender Nayak, hereinafter referring to Takeda) announced ‘Edarbi(potassium azilsartan medoxomil),’ an essential hypertensive treatment, acquired commercialization approval from the Ministry of Food and Drug Safety on the 29th.
‘Edarbi,’ an angiotensin II recept...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
